Completed PHASE2 INTERVENTIONAL 2-arm NCT01530503

Second Line Therapy in Advanced Biliary Tract Cancer (BIT-2)

A Randomized Phase II Trial of Second Line Therapy in Advanced Biliary Tract Cancer: Capecitabine or Capecitabine Plus Mitomycin C

Sponsor: IRCCS San Raffaele

Conditions Biliary Tract Cancer

Interventions Capecitabine capecitabine and mitomycin

Updated 6 times since 2017 Last updated: Feb 24, 2016 Started: Nov 30, 2011 Primary completion: Oct 31, 2013 Completion: Oct 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01530503, this PHASE2 trial focuses on Biliary Tract Cancer and remains completed. Sponsored by IRCCS San Raffaele, it has been updated 6 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IRCCS San Raffaele
Regione Lombardia

Data source: IRCCS San Raffaele

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Bergamo, Italy , Bologna, Italy , Candiolo (Torino), Italy , Catania, Italy , Cefalù, Italy , Fabriano, Italy , Milan, Italy , Padua, Italy , Pisa, Italy and 6 more locations